Analysts fell to the sidelines weighing in on Myriad Genetics (MYGN – Research Report), Pfizer (PFE – Research Report) and RegenXBio (RGNX – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Myriad Genetics (MYGN) In a report issued on August 12, Puneet Souda from SVB Securities maintained a Hold rating on Myriad Genetics. The company's shares closed last Monday at $27.88. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-myriad-genetics-mygn-pfizer-pfe?utm_source=advfn.com&utm_medium=referral
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more REGENXBIO Charts.
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more REGENXBIO Charts.